The Kingsley Clinic

Cutaneous Lupus Erythematosus: Symptoms, Risks, and Treatment Guide

Introduction

Cutaneous lupus erythematosus (CLE) is a chronic autoimmune condition that primarily affects the skin. It is a form of lupus, where the immune system mistakenly targets healthy tissues. CLE can lead to various skin-related symptoms, including rashes, lesions, and heightened sensitivity to sunlight. While not life-threatening, the condition can significantly impact a person’s quality of life due to visible symptoms and the potential for scarring. The history of lupus dates back to the 19th century, when it was first described by French dermatologist Pierre Cazenave. Since then, medical advancements have deepened our understanding of CLE, though it remains a complex condition to manage.

This article aims to provide a comprehensive overview of CLE, covering its risk factors, symptoms, diagnostic tests, treatment options, and self-care strategies. By understanding these aspects, patients can better manage their condition and work closely with healthcare providers to develop an effective treatment plan.

Definition of Cutaneous Lupus Erythematosus

Cutaneous lupus erythematosus is a skin-related autoimmune disorder that involves several key components: risk factors, symptoms, diagnostic tests, medications, procedures, and home-care strategies to manage symptoms.

Description of Cutaneous Lupus Erythematosus

Cutaneous lupus erythematosus (CLE) is a form of lupus that primarily affects the skin. It belongs to a broader category of autoimmune diseases in which the immune system mistakenly attacks the body’s own tissues. In CLE, this immune response leads to inflammation and skin damage, resulting in rashes, lesions, and other skin abnormalities. There are three main subtypes of CLE: acute cutaneous lupus erythematosus (ACLE), subacute cutaneous lupus erythematosus (SCLE), and chronic cutaneous lupus erythematosus (CCLE), which includes discoid lupus erythematosus (DLE).

The course of CLE can vary widely. Some individuals may experience mild, intermittent symptoms, while others may face more severe, persistent skin issues. In some cases, CLE can lead to permanent scarring or skin discoloration. Although CLE primarily affects the skin, it can sometimes be associated with systemic lupus erythematosus (SLE), a more severe form of lupus that affects multiple organs.

According to the Lupus Foundation of America, approximately 1.5 million Americans have some form of lupus, with about two-thirds experiencing cutaneous involvement. CLE is more common in women than men and typically develops between the ages of 20 and 50, though it can occur in people of all ages and ethnic backgrounds.

Risk Factors for Developing Cutaneous Lupus Erythematosus

Lifestyle Risk Factors

Certain lifestyle factors can increase the risk of developing CLE or worsen existing symptoms. One significant risk factor is exposure to ultraviolet (UV) light, such as sunlight or tanning beds. UV light can trigger or exacerbate skin lesions in people with CLE. As a result, individuals with CLE are often advised to limit sun exposure and use broad-spectrum sunscreen with a high SPF.

Smoking is another lifestyle factor that can negatively affect CLE. Research indicates that smoking can worsen skin lesions and reduce the effectiveness of certain treatments. Quitting smoking is strongly recommended for individuals with CLE to improve both skin health and overall well-being.

Stress is also known to trigger lupus flares, including those affecting the skin. Managing stress through relaxation techniques, regular exercise, and adequate sleep can help reduce the frequency and severity of CLE symptoms.

Medical Risk Factors

Several medical conditions and factors can increase the likelihood of developing CLE. Individuals with a history of autoimmune diseases, such as rheumatoid arthritis or Sjögren’s syndrome, may be at higher risk. Additionally, people with systemic lupus erythematosus (SLE) are more likely to experience cutaneous manifestations of the disease.

Certain medications, such as antihypertensives, anticonvulsants, and antibiotics, have been linked to drug-induced lupus, which can include skin symptoms similar to CLE. If you are taking any of these medications and notice skin changes, consult your healthcare provider.

Hormonal changes, particularly in women, can also play a role in the development of CLE. Pregnancy, menstruation, and hormone replacement therapy may trigger lupus flares, including skin-related symptoms.

Genetic and Age-Related Risk Factors

Genetics play a significant role in the development of CLE. Individuals with a family history of lupus or other autoimmune diseases are at higher risk. While the exact genetic factors are not fully understood, researchers believe certain genes may predispose individuals to autoimmune conditions like lupus.

Age is another factor. Although CLE can occur at any age, it is most commonly diagnosed in adults between 20 and 50. However, children and older adults can also develop the condition. Women are more likely to be affected by CLE than men, with a female-to-male ratio of approximately 3:1.

Ethnicity may also influence the risk of developing CLE. Studies show that lupus, including its cutaneous forms, is more prevalent in people of African, Hispanic, and Asian descent compared to Caucasians. This may be due to genetic and environmental factors that are still being studied.

Clinical Manifestations of Cutaneous Lupus Erythematosus

Skin Rash

Skin rashes occur in approximately 70-80% of patients with cutaneous lupus erythematosus (CLE). These rashes often appear as red, scaly patches or plaques on sun-exposed areas such as the face, neck, and arms. The immune system mistakenly attacks healthy skin cells, leading to inflammation and the characteristic rash. The severity of the rash can vary and may worsen with sun exposure, a phenomenon known as photosensitivity. Early in the disease, the rash may be mild, but it can become more pronounced as the condition progresses.

Photosensitivity

Photosensitivity affects about 50-60% of CLE patients. It refers to an abnormal skin reaction to ultraviolet (UV) light, typically from sunlight. In individuals with CLE, exposure to UV light can trigger or worsen skin lesions. This occurs because UV light can damage skin cells, prompting an immune response that leads to inflammation. Photosensitivity is often one of the earliest signs of CLE and can be more pronounced in individuals with lighter skin tones. Patients are advised to avoid direct sunlight and use protective measures such as sunscreen and sun-protective clothing.

Discoid Lesions

Discoid lesions are present in about 20-40% of CLE patients. These are thick, scaly, coin-shaped patches that can appear on the scalp, face, and other sun-exposed areas. Discoid lesions are a hallmark of discoid lupus erythematosus (DLE), a subtype of CLE. These lesions can cause permanent scarring and hair loss if they occur on the scalp. The immune system’s attack on the skin leads to chronic inflammation, which causes the thickening and scaling of the skin. Early treatment is crucial to prevent long-term damage.

Erythema

Erythema, or redness of the skin, is seen in around 60-70% of CLE patients. This redness is caused by increased blood flow to the affected areas due to inflammation. Erythema often accompanies other skin manifestations like rashes or discoid lesions and is typically more noticeable in fair-skinned individuals. The redness may worsen with sun exposure or during flare-ups of the disease. Erythema can be a sign of active inflammation and may require prompt treatment to prevent further skin damage.

Scaling

Scaling, or the shedding of the outer layer of skin, occurs in approximately 40-50% of CLE patients. It is often seen in conjunction with rashes or discoid lesions. The immune system’s attack on the skin leads to the rapid turnover of skin cells, resulting in the formation of dry, flaky patches. Scaling can be uncomfortable and may cause itching or irritation. Moisturizers and topical treatments are often recommended to alleviate this symptom.

Itching

Itching affects about 30-40% of individuals with CLE. It is often associated with skin rashes, scaling, or discoid lesions. The inflammation caused by the immune system’s attack on the skin can irritate nerve endings, leading to itching. Scratching can worsen the condition by causing further damage to the skin and increasing the risk of infection. Itching may be more severe during flare-ups or after sun exposure. Topical corticosteroids or antihistamines may be prescribed to relieve itching.

Hair Loss

Hair loss, or alopecia, occurs in approximately 20-30% of CLE patients, particularly those with discoid lesions on the scalp. The inflammation caused by the immune system’s attack on hair follicles can lead to hair thinning or bald patches. In some cases, the hair loss may be temporary, but if scarring occurs, it can become permanent. Early treatment of scalp lesions is essential to prevent irreversible hair loss. Patients may also experience diffuse hair thinning, known as telogen effluvium, during disease flare-ups.

Ulcerations

Ulcerations, or open sores, are less common in CLE, affecting about 10-15% of patients. These sores can develop on the skin or mucous membranes, such as the inside of the mouth or nose. Ulcerations occur when the immune system’s attack on the skin leads to the breakdown of tissue. These sores can be painful and may take a long time to heal. In some cases, they can become infected, requiring additional treatment. Ulcerations are more likely to occur in severe or advanced cases of CLE.

Pigmentation Changes

Pigmentation changes, including both hyperpigmentation (darkening of the skin) and hypopigmentation (lightening of the skin), occur in about 30-40% of CLE patients. These changes are often seen after the healing of skin lesions. The immune system’s attack on the skin can disrupt the production of melanin, the pigment responsible for skin color. Hyperpigmentation is more common in individuals with darker skin tones, while hypopigmentation may be more noticeable in lighter-skinned individuals. These changes can be long-lasting and may cause cosmetic concerns for patients.

Telangiectasia

Telangiectasia, or the appearance of small, dilated blood vessels on the skin, occurs in about 10-20% of CLE patients. These visible blood vessels are often found on the face, particularly around the nose and cheeks. Telangiectasia is caused by chronic inflammation and damage to the blood vessels in the skin. While not harmful, it can be a cosmetic concern for some patients. Laser treatments may be used to reduce the appearance of telangiectasia.

Treatment Options for Cutaneous Lupus Erythematosus

Medications for Skin Lupus

Hydroxychloroquine

Hydroxychloroquine, an antimalarial medication, is commonly prescribed to treat autoimmune conditions like cutaneous lupus erythematosus (CLE). It works by reducing inflammation and modulating the immune system, helping to alleviate skin symptoms and prevent flare-ups.

As a first-line treatment for CLE, hydroxychloroquine is generally well-tolerated with a relatively mild side effect profile. It is typically prescribed for mild to moderate skin involvement and is taken orally, once or twice daily.

Patients often notice improvements within 1 to 3 months of starting hydroxychloroquine. Long-term use can help prevent future flare-ups, but regular monitoring is essential to avoid potential side effects, such as retinal damage.

Corticosteroids

Corticosteroids are anti-inflammatory medications that can be applied topically, taken orally, or administered by injection to reduce inflammation and suppress the immune response in CLE.

Topical corticosteroids are commonly used for localized skin lesions, while oral or injectable forms are reserved for more severe or widespread cases. These medications are generally used short-term to control acute flare-ups.

Patients may experience rapid improvement within days to weeks of starting corticosteroids. However, long-term use is discouraged due to risks such as skin thinning, weight gain, and increased susceptibility to infections.

Methotrexate

Methotrexate is an immunosuppressive medication that reduces immune system activity, which can be overactive in CLE patients.

It is typically prescribed for individuals who do not respond well to first-line treatments like hydroxychloroquine or corticosteroids. Methotrexate is taken orally or by injection, usually once a week.

Improvements in skin symptoms may be seen within 4 to 6 weeks. Regular blood tests are required to monitor for side effects, such as liver damage and low blood cell counts.

Azathioprine

Azathioprine is another immunosuppressive medication that helps control inflammation and prevent flare-ups in CLE by reducing immune system activity.

It is often used in patients who do not respond to or cannot tolerate other treatments like hydroxychloroquine or methotrexate. Azathioprine is taken orally, usually once or twice daily.

Improvements in skin symptoms may take several weeks to months. Regular monitoring is necessary to check for side effects, such as liver toxicity and low blood cell counts.

Belimumab

Belimumab is a biologic medication that targets specific proteins involved in the immune response, helping to reduce inflammation and prevent flare-ups in CLE.

It is typically reserved for more severe or refractory cases of CLE that do not respond to other treatments. Belimumab is administered by injection or infusion, usually every 2 to 4 weeks.

Patients may see improvements within a few months of starting belimumab. Regular monitoring is required to assess for side effects, such as infections and allergic reactions.

Dapsone

Dapsone is an anti-inflammatory and antibiotic medication that helps reduce skin inflammation in CLE patients.

It is often used for mild to moderate CLE in patients who do not respond well to other treatments. Dapsone is taken orally, usually once or twice daily.

Improvements in skin symptoms may be noticed within a few weeks. Regular blood tests are necessary to monitor for side effects, such as anemia and liver toxicity.

Minocycline

Minocycline is an antibiotic with anti-inflammatory properties, making it useful for treating skin inflammation in CLE.

It is typically used for mild to moderate CLE in patients who do not respond to other treatments. Minocycline is taken orally, usually once or twice daily.

Patients may see improvements within a few weeks. Side effects may include gastrointestinal upset and skin discoloration.

Mycophenolate Mofetil

Mycophenolate mofetil is an immunosuppressive medication that reduces immune system activity, which can be overactive in CLE patients.

It is often used for more severe or refractory cases of CLE that do not respond to other treatments. Mycophenolate mofetil is taken orally, usually twice daily.

Improvements in skin symptoms may take several weeks to months. Regular monitoring is necessary to check for side effects, such as infections and gastrointestinal issues.

Tacrolimus

Tacrolimus is a topical immunosuppressive medication that reduces inflammation and controls skin symptoms in CLE.

It is typically used for localized skin lesions, especially in sensitive areas like the face. Tacrolimus is applied directly to the affected skin, usually twice daily.

Improvements in skin symptoms may be noticed within a few weeks. Side effects may include skin irritation and an increased risk of skin infections.

Retinoids

Retinoids, derived from vitamin A, help regulate skin cell turnover and reduce inflammation in CLE.

These medications are typically used for more severe or scarring forms of CLE. Retinoids can be taken orally or applied topically, depending on the formulation.

Improvements in skin symptoms may be seen within a few weeks to months. Side effects may include dry skin, irritation, and increased sensitivity to sunlight.

Improving Cutaneous Lupus Erythematosus and Seeking Medical Help

In addition to medical treatments, several home remedies and lifestyle changes can help manage cutaneous lupus erythematosus (CLE) and improve your quality of life:

  1. Sunscreen: Use a broad-spectrum sunscreen with an SPF of 30 or higher daily to protect your skin from UV rays, which can trigger flare-ups.
  2. Wearing protective clothing: Long sleeves, wide-brimmed hats, and sunglasses can shield your skin from harmful sun exposure.
  3. Avoiding sun exposure: Stay indoors during peak sunlight hours (10 a.m. to 4 p.m.) to minimize UV exposure.
  4. Stress management: Practice relaxation techniques like meditation or yoga to reduce stress, which can trigger flare-ups.
  5. Maintaining a healthy diet: A balanced diet rich in fruits, vegetables, and lean proteins supports your immune system and overall health.
  6. Staying hydrated: Drink plenty of water to keep your skin hydrated and healthy.
  7. Regular exercise: Moderate physical activity improves circulation and reduces inflammation.
  8. Using gentle skin care products: Opt for fragrance-free, hypoallergenic products to avoid irritating your skin.
  9. Avoiding harsh chemicals: Stay away from products with alcohol, sulfates, or other harsh ingredients that can aggravate your skin.
  10. Getting adequate sleep: Aim for 7-9 hours of sleep per night to help your body heal and reduce stress.

If you experience worsening symptoms or new lesions, seek medical help. Telemedicine offers a convenient way to consult with healthcare providers from the comfort of your home. Through virtual visits, you can receive timely advice, medication adjustments, and follow-up care without the need for in-person appointments.

Living with Cutaneous Lupus Erythematosus: Tips for Better Quality of Life

Living with cutaneous lupus erythematosus can be challenging, but there are steps you can take to improve your quality of life:

  1. Follow your treatment plan as prescribed by your healthcare provider to manage symptoms and prevent flare-ups.
  2. Stay informed about your condition and communicate openly with your healthcare team about any concerns or changes in your symptoms.
  3. Practice self-care by protecting your skin from the sun, managing stress, and maintaining a healthy lifestyle.
  4. Join a support group or connect with others who have lupus to share experiences and coping strategies.
  5. Consider telemedicine for regular check-ins with your healthcare provider, which can save time and reduce the stress of traveling to appointments.

Conclusion

Cutaneous lupus erythematosus is a chronic autoimmune condition that primarily affects the skin, causing rashes, lesions, and other symptoms. Early diagnosis and treatment are essential for managing the condition and preventing complications. By working closely with your healthcare provider and following a comprehensive treatment plan, you can reduce flare-ups and improve your quality of life.

If you’re experiencing symptoms of cutaneous lupus erythematosus, our telemedicine practice is here to help. Schedule a virtual consultation with one of our primary care providers to discuss your symptoms, treatment options, and next steps for managing your condition.

James Kingsley
James Kingsley

Learn More
Scroll to Top